대표어
한국학술지인용색인(NRF)
권호기사보기
| 기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
|---|
국회도서관 홈으로
정보검색
소장정보 검색
결과 내 검색
동의어 포함
목차보기
Contents
High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma : 10-year experience at a single center / Jung Min Suh ; Keon Hee Yoo ; Ki Woong Sung ; Ju Youn Kim ; Eun Joo Cho ; Hong Hoe Koo ; Suk Koo Lee ; Jhingook Kim ; Do Hoon Lim ; Yeon Lim Suh ; Dae Won Kim 1
[요약] 1
Introduction 1
Materials and methods 2
Patients 2
Treatment of patients 2
PBSC collection 3
HDCT and ASCR 3
Local radiotherapy 3
Post-HDCT treatment 3
Response criteria 3
Statistics 3
Results 3
Patient characteristics 3
Treatment prior to HDCT/ASCR 4
Feasibility of PBSC collection 4
HDCT/ASCR 4
Feasibility of post-HDCT/ASCR therapy 5
Survival of patients 5
Discussion 6
ACKNOWLEDGMENTS 7
REFERENCES 7
초록보기
High-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was
applied to improve the prognosis of patients with high-risk stage 3 neuroblastoma.
From January 1997 to December 2006, 28 patients were newly diagnosed as stage
3 neuroblastoma. Nine of 11 patients with N-myc amplification and 5 of 17 patients
without N-myc amplification (poor response in 2 patients, persistent residual tumor
in 2 and relapse in 1) underwent single or tandem HDCT/ASCR. Patients without
high-risk features received conventional treatment modalities only. While 8 of 9
patients underwent single HDCT/ASCR and the remaining one patient underwent
tandem HDCT/ASCR during the early study period, all 5 patients underwent tandem
HDCT/ASCR during the late period. Toxicities associated with HDCT/ASCR
were tolerable and there was no treatment-related mortality. While the tumor relapsed
in two of eight patients in single HDCT/ASCR group, all six patients in tandem HDCT/
ASCR group remained relapse free. The 5-yr event-free survival (EFS) from diagnosis,
in patients with N-myc amplification, was 71.6?4.0%. In addition, 12 of 14
patients who underwent HDCT/ASCR remained event free resulting in an 85.1?
9.7% 5-yr EFS after the first HDCT/ASCR. The present study demonstrates that
HDCT/ASCR may improve the survival of patients with high-risk stage 3 neuroblastoma.권호기사
참고문헌 (22건) : 자료제공( 네이버학술정보 )
| 번호 | 참고문헌 | 국회도서관 소장유무 |
|---|---|---|
| 1 | Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.  |
미소장 |
| 2 | The biologic basis for neuroblastoma heterogeneity and risk stratification. |
미소장 |
| 3 | N-Myc Gene Amplification Is a Major Prognostic Factor in Localized Neuroblastoma: Results of the French NBL 90 Study |
미소장 |
| 4 | Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting |
미소장 |
| 5 | The impact of gross total resection on local control and survival in high-risk neuroblastoma |
미소장 |
| 6 | The impact of surgical radicality on outcome in childhood neuroblastoma. |
미소장 |
| 7 | Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. |
미소장 |
| 8 | Autologous bone marrow transplantation for recurrent malignant lymphoma after liver transplantation. |
미소장 |
| 9 | Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. |
미소장 |
| 10 | Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. |
미소장 |
| 11 | Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial |
미소장 |
| 12 | Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. |
미소장 |
| 13 | High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. |
미소장 |
| 14 | Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. |
미소장 |
| 15 | Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. |
미소장 |
| 16 | Pession A, Prete A, Locatelli F, Pierinelli S, Pession AL, Maccario R, Magrini E, De Bernardi B, Paolucci P, Paolucci G. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 1998; 78: 528-33. | 미소장 |
| 17 | Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL, Fourquet B, Valteau-Couanet D, Bergeron C, Philip T, Carrie C. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys 2006; 64: 1424-31. | 미소장 |
| 18 | Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. |
미소장 |
| 19 | Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992; 20: 307-11. | 미소장 |
| 20 | Kohler JA, Imeson J, Ellershaw C, Lie SO. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000; 83: 1124-7. | 미소장 |
| 21 | Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br J Cancer 2000; 83: 1121-3. | 미소장 |
| 22 | Shin MY, Ahn KM, Sung KW, Koo HH. Immunotherapy with interleukin-2 after autologous stem cell transplantation in children with high-risk solid tumor. Korean J Hematol Stem Cell Trans 1999; 4: 239-48. | 미소장 |
MARC 보기
오류 데이터 정정요청
*표시는 필수 입력사항입니다.
알림톡 발송
| 전화번호 |
|---|
개인정보 수정 바로가기
연속간행물 권호 선택
우편복사 안내
- ◾ 도서관을 방문하지 못할 경우 인터넷, 팩스 등으로 자료 복사를 신청하고, 복사물을 우편·팩스 등으로 제공받는 서비스
- ◾ 대상자료: 일반도서, 연속간행물 및 학위논문
- ※ 고서, 고잡지, 훼손될 우려가 있는 자료, 마이크로폼 자료 및 신문 등 제외
- ◾ 신청 책수: 1인 5책 이하(1일 기준)
- ◾ 신청 절차: 자료 검색 → 우편복사 목록담기 → 복사 범위 입력 → 우편복사 주문서 입력 → 접수 및 확인
- ※ 저작권법에 의거하여 부분 복사(전체 페이지 수의 1/3 범위 이내)만 가능
- ◾ 복사 범위 입력 예시: (연속 페이지) 1-30, (부분 페이지) 25, 30-40
| 번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
|---|
도서위치안내(서울관)
도서위치안내: 정기간행물실(524호) / 서가번호: 국내17
2021년 이전 정기간행물은 온라인 신청(원문 구축 자료는 원문 이용)
0
확인
우편복사 목록담기를 완료하였습니다.
내서재에 담기
새로운 서재
*표시는 필수 입력사항입니다.
저장
저장 되었습니다.